ImmunoPrecise Antibodies Ltd. (HYFT) — Cash Flow-to-Debt Ratio
ImmunoPrecise Antibodies Ltd. (HYFT) has a Cash Flow-to-Debt Ratio of -0.34x as of October 2025, meaning its operating cash flow of $-2.87 Million could theoretically repay 0% of its total liabilities ($8.40 Million) in one year. Explore how much of ImmunoPrecise Antibodies Ltd.'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ImmunoPrecise Antibodies Ltd. Cash Flow-to-Debt Ratio (1997–2025)
Historical debt coverage capacity for ImmunoPrecise Antibodies Ltd. across 29 annual periods. Also explore ImmunoPrecise Antibodies Ltd. (HYFT) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for ImmunoPrecise Antibodies Ltd. (1997–2025)
Year-by-year debt coverage analysis for ImmunoPrecise Antibodies Ltd.. For market capitalisation and broader financial context, see ImmunoPrecise Antibodies Ltd. stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.31x | $-6.41 Million | $20.82 Million | ▼ -89.1% |
| 2024 | -0.16x | $-4.25 Million | $26.07 Million | ▲ +83.6% |
| 2023 | -0.99x | $-19.83 Million | $20.01 Million | ▼ -83.4% |
| 2022 | -0.54x | $-9.92 Million | $18.36 Million | ▼ -803.7% |
| 2021 | -0.06x | $-600.00K | $10.04 Million | ▲ +47.7% |
| 2020 | -0.11x | $-1.39 Million | $12.18 Million | ▲ +63.4% |
| 2019 | -0.31x | $-3.21 Million | $10.28 Million | ▼ -8.4% |
| 2018 | -0.29x | $-3.42 Million | $11.87 Million | ▲ +66.6% |
| 2017 | -0.86x | $-721.65K | $836.91K | ▼ -243.3% |
| 2016 | 0.60x | $284.09K | $472.15K | ▲ +524.3% |
| 2015 | -0.14x | $-36.11K | $254.64K | ▲ +7.7% |
| 2014 | -0.15x | $-46.60K | $303.50K | ▼ -840.9% |
| 2013 | -0.02x | $-4.33K | $265.63K | ▲ +97.4% |
| 2012 | -0.62x | $-132.72K | $213.10K | ▲ +34.0% |
| 2011 | -0.94x | $-80.39K | $85.19K | ▲ +69.3% |
| 2010 | -3.07x | $-308.49K | $100.47K | ▼ -197.5% |
| 2009 | -1.03x | $-155.68K | $150.84K | ▲ +92.6% |
| 2008 | -13.97x | $-523.45K | $37.46K | ▼ -632.5% |
| 2007 | -1.91x | $-297.31K | $155.85K | ▼ -139.1% |
| 2006 | -0.80x | $-110.59K | $138.62K | ▲ +54.2% |
| 2005 | -1.74x | $-82.20K | $47.18K | ▲ +51.3% |
| 2004 | -3.58x | $-178.69K | $49.92K | ▲ +65.9% |
| 2003 | -10.51x | $-168.38K | $16.02K | ▼ -604.0% |
| 2002 | -1.49x | $-280.23K | $187.72K | ▼ -16357.5% |
| 2001 | -0.01x | $-8.13K | $896.75K | ▲ +100.0% |
| 2000 | -20.63x | $-208.54K | $10.11K | ▼ -263.7% |
| 1999 | -5.67x | $-202.94K | $35.78K | ▼ -68.5% |
| 1998 | -3.37x | $-226.81K | $67.39K | ▼ -677.8% |
| 1997 | -0.43x | $-108.20K | $250.04K | — |